Stockscreener 앱 받기
7.71
3.49%
0.26
시간 외 거래:
7.70
-0.010
-0.13%
전일 마감가:
$7.45
열려 있는:
$8
하루 거래량:
33.73M
Relative Volume:
5.51
시가총액:
$698.24M
수익:
$30.91M
순이익/손실:
$-209.47M
주가수익비율:
-2.3168
EPS:
-3.3279
순현금흐름:
$-147.13M
1주 성능:
-6.72%
1개월 성능:
+2.66%
6개월 성능:
+25.57%
1년 성능:
-14.33%
1일 변동 폭
$6.70
$8.955
1주일 범위
$6.70
$8.955
52주 변동 폭
$3.43
$10.82
Verastem Inc Stock (VSTM) Company Profile
명칭
Verastem Inc
전화
(781) 292-4200
주소
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
7.71 | 698.24M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
498.50 | 126.35B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
226.30 | 90.35B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
778.36 | 80.14B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
818.30 | 51.46B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.52 | 41.48B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-17 | 개시 | Wolfe Research | Outperform |
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2026-02-04 | 개시 | H.C. Wainwright | Buy |
| 2025-10-16 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-04-10 | 개시 | Jefferies | Buy |
| 2025-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-31 | 재확인 | BTIG Research | Buy |
| 2024-09-30 | 개시 | Guggenheim | Buy |
| 2023-11-21 | 재개 | BTIG Research | Buy |
| 2023-09-27 | 개시 | B. Riley Securities | Buy |
| 2023-06-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2022-09-07 | 재개 | Alliance Global Partners | Buy |
| 2022-04-29 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 개시 | RBC Capital Mkts | Outperform |
| 2022-03-09 | 개시 | Truist | Buy |
| 2021-07-01 | 개시 | Alliance Global Partners | Buy |
| 2021-05-24 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2019-06-20 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 개시 | BTIG Research | Buy |
| 2018-05-02 | 개시 | Seaport Global Securities | Buy |
| 2018-03-08 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-13 | 개시 | Oppenheimer | Outperform |
| 2017-03-24 | 재확인 | H.C. Wainwright | Buy |
| 2015-09-29 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-09-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2015-09-28 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-05-12 | 재확인 | UBS | Buy |
| 2015-04-08 | 개시 | H.C. Wainwright | Buy |
| 2015-01-23 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Oppenheimer | Perform |
| 2014-02-11 | 개시 | Mizuho | Buy |
모두보기
Verastem Inc 주식(VSTM)의 최신 뉴스
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect? - Zacks Investment Research
BTIG reiterates Buy rating on Verastem, $18 price target - TradingView
BTIG keeps its Buy rating for Verastem stock - AD HOC NEWS
This Insider Has Just Sold Shares In Verastem - Simply Wall Street
This Insider Has Just Sold Shares In Verastem - Simply Wall Street
Verastem's cancer drug sales hit $25.1M in Q2 '26; key trial data expected in October - Pluang
Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch (NASDAQ:VSTM) - Seeking Alpha
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
VSTM Reiterates by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 - BioSpace
To cover tax withholding, Verastem (VSTM) CEO sells 44,121 shares at $8 each. - Stock Titan
A 2,566-share sale at $8 covers vesting taxes for Verastem (VSTM) CFO Daniel Calkins. - Stock Titan
To cover vesting taxes, Dan Paterson plans to sell 44,121 shares of Verastem (VSTM). - Stock Titan
Preferred dividends of Verastem, Inc. – HAN:2VSA - TradingView
Discontinued operations of Verastem, Inc. – HAN:2VSA - TradingView
Verastem, Inc. Actuals & Estimates (HAN:2VSA) - TradingView
Verastem (NasdaqCM:VSTM) Stock Forecast & Analyst Predictions - Simply Wall Street
Verastem (VSTM) Shares React to Positive Two-Year Phase 2 RAMP 201 Study Results in Ovarian Cancer - GuruFocus
Half of patients with a specific ovarian cancer mutation stayed on treatment for over a year. - Stock Titan
Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data - Investing.com
Understanding the Setup: (VSTM) and Scalable Risk - Stock Traders Daily
Verastem to present cancer treatment study data at IGCS meeting - Investing.com
Two ovarian cancer studies are selected for Montreal talks. One studied Japanese patients. - Stock Titan
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire
Verastem CFO Daniel Calkins sells $423 in company stock - Investing.com
Form 4 Verastem Inc For: 23 September - Investing.com India
Verastem CFO Daniel Calkins sells $423 in company stock By Investing.com - Investing.com Canada
Verastem (VSTM) CFO Daniel Calkins Sells 55 Shares, Insider Owne - GuruFocus
After selling 55 shares, Verastem (VSTM) CFO Daniel Calkins directly owned 118,014 shares. - Stock Titan
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - Yahoo Finance
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - TradingView
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Verastem Inc. Share PriceVSTM, RNS News, Articles, Quotes, & Charts (NASDAQ:VSTM) - Proactive financial news
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - marketscreener.com
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - Yahoo Finance
Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 94% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Verastem Repeat Insider Selling Not A Positive Indicator - Moomoo
Wolfe Research Initiates Verastem at Outperform - Yahoo Finance
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus
Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com India
Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com Canada
VSTM: Verastem Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Verastem Inc (VSTM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verastem Inc 주식 (VSTM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dan Paterson | Officer, Director |
Oct 01 '26 |
Proposed Sale |
8.00 |
44,121 |
353,047 |
0 |
| Calkins Daniel | Chief Financial Officer |
Oct 01 '26 |
Sale |
8.00 |
2,566 |
20,528 |
123,781 |
| Calkins Daniel | Chief Financial Officer |
Sep 21 '26 |
Sale |
7.70 |
55 |
424 |
118,014 |
| Paterson Dan | President and CEO |
Aug 03 '26 |
Sale |
5.81 |
1,302 |
7,565 |
589,940 |
| Gagnon Robert E. | Director |
Jul 23 '26 |
Proposed Sale |
5.89 |
31,924 |
188,032 |
0 |
| Gagnon Robert E. | Director |
Jun 25 '26 |
Proposed Sale |
4.21 |
21,492 |
90,481 |
0 |
| Dan Paterson | Officer, Director |
Jun 22 '26 |
Proposed Sale |
4.18 |
20,871 |
87,241 |
0 |
| Calkins Daniel | Chief Financial Officer |
Jun 22 '26 |
Sale |
4.18 |
4,089 |
17,089 |
117,238 |
| Paterson Dan | President and CEO |
Jun 22 '26 |
Sale |
4.18 |
20,871 |
87,241 |
591,242 |
| Gagnon Robert E. | Director |
May 27 '26 |
Proposed Sale |
4.36 |
20,103 |
87,649 |
0 |
3.32%
자본화:
|
볼륨(24시간):